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OBJECTIVE—Hyperglycemia impairs angiogenesis in response
to ischemia, leading to ventricular remodeling. Although the
effects of overexpressing angiogenic growth factors have been
studied in inducing angiogenesis, the formation of functional
vessels remains a challenge. The present study evaluates the
reversal of diabetes-mediated impairment of angiogenesis in the
infarcted diabetic rat myocardium by proangiogenic gene
therapy.
RESEARCH DESIGN AND METHODS—Ad.VEGF and
Ad.Ang1 were intramyocardially administered in combination
immediately after myocardial infarction to nondiabetic and dia-
betic rats. Ad.LacZ was similarly administered to the respective
control groups. The hearts were excised for molecular and
immunohistochemical analysis at predetermined time points.
The myocardial function was measured by echocardiography 30
days after the intervention.
RESULTS—We observed reduced ﬁbrosis and increased capil-
lary/arteriolar density along with reduced ventricular remodel-
ing, as assessed by echocardiography in the treated diabetic
animals compared with the nontreated diabetic controls. We also
observed increased phosphorylated mitogen-activated protein
kinase–activated protein kinase-2, 2 days after the treatment and
increased expression of vascular endothelial growth factor
(VEGF), Flk-1, angiopoietin-1 (Ang-1), Tie-2, and survivin, 4 days
after treatment in the diabetic animals. Gel shift analysis revealed
that the combination gene therapy stimulated the DNA binding
activity of nuclear factor-B in the diabetic animals.
CONCLUSIONS—Our preclinical data demonstrate the efﬁcacy
of coadministration of adenoviral VEGF and Ang-1 in increasing
angiogenesis and reducing ventricular remodeling in the in-
farcted diabetic myocardium. These unique results call for the
initiation of a clinical trial to assess the efﬁcacy of this therapeu-
tic strategy in the treatment of diabetes-related human heart
failure. Diabetes 59:51–60, 2010
D
iabetic individuals who develop an ischemic
heart disease (IHD) sustain an unfavorable
prognosis for survival compared with other IHD
subjects without diabetes (1). This condition
may be attributed to impaired coronary collateral vessel
development and reduced myocardial vascular perfusion
in response to ischemia, leading to profound ventricular
remodeling and subsequent heart failure (2). Various stud-
ies have linked diabetes-mediated impaired myocardial
angiogenesis to alterations in the delicate balance of
angiogenic growth factors and cytokines regulating vascu-
lar stability (2–4) and compromised signal transduction
(4). Several studies have reported the possible role of
decreased vascular endothelial growth factor (VEGF) and
angiopoietin-1 (Ang-1) in the pathogenesis of diabetes-
mediated impairment of angiogenesis in the myocardium
(5–7).
There have been several attempts at preclinical and
clinical levels to induce angiogenesis by overexpressing
angiogenic factors in the peri-infarct zone after myocardial
infarction (MI). Most of the studies have approached this
issue using a single gene as the therapeutic agent. Delivery
of vectors encoding VEGF165 (VEGF) and VEGF-2 was
shown to improve collateral vascular perfusion and nour-
ish the oxygen-depleted myocardium, thereby reducing
angina and improving heart function in human clinical
trials (8–10). However, investigations into the long-term
effects of sustained expression of VEGF in mice models
revealed deleterious effects due to the formation of leaky
immature vessels/hemangiomas and subsequent death of
the experimental animal (11,12). Furthermore, transgenic
mice overexpressing VEGF revealed lengthy and leaky
dermal vessels with evident inﬂammation (13,14).
On the other hand, the Ang-1 system is known to play a
critical role in vascular maturation and stabilization,
thereby supporting VEGF-induced neovascularization in a
complementary manner (6,14,15). Recently, Ang-1 gene
therapy has been shown to support the maturation of the
immature vasculature in db/db mice (16).
In the recent past, work has been done to elucidate
the synergistic effect of coadministration of VEGF and
Ang-1 in ischemic rat myocardium (17–19). Zhou et al.
(18) reported that combined gene therapy using VEGF
and Ang-1 signiﬁcantly reduced myocardial infarct size
through the induction of the phosphatidylinositol 3-kinase
and Bcl-2 survival pathways and nuclear factor-B
(NFB) activation.
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VEGF and Ang-1 encoding vectors to activate the angio-
genic signaling cascade has not yet been explored in the
diabetic ischemic myocardium. Diabetes reﬂects a far
more challenging condition, where the VEGF and Ang-1
system is signiﬁcantly downregulated, hampering the abil-
ity of the myocardium to respond to an ischemic stress
(2,6), and where the usual revascularization techniques
such as coronary artery bypass graft and percutaneous
transluminal coronary angioplasty tend to fail, thereby
leaving many of the diabetic IHD subjects with no option.
Therefore, in this study we aimed at using a combination
gene therapy approach involving in vivo adenoviral gene
delivery of VEGF and Ang-1, to enhance neoangiogenesis
by repairing the impaired angiogenic signaling cascade
and thereby reducing ventricular remodeling in streptozo-
tocin (STZ)-induced type 1 diabetic rats. Our ﬁndings
emphasize the efﬁcacy of coadministration of adenoviral
vectors encoding VEGF and Ang-1 in inducing and stabi-
lizing the process of angiogenesis that is impaired in the
diabetic myocardium and in reducing ventricular remod-
eling in the infarcted myocardium in a diabetic milieu,
thereby supporting the development of a combination
gene therapy for therapeutic myocardial angiogenesis.
RESEARCH DESIGN AND METHODS
Experimental animals. This study was performed in accordance with the
principles of laboratory animal care formulated by the National Society for
Medical Research and with the Guide for the Care and Use of Laboratory
Animals (20). The experimental protocol was approved by the Institutional
Animal Care Committee of the University of Connecticut Health Center
(Farmington, CT). Male SD rats (300–325 g) were randomly separated into
normal and diabetic rats as they received an intraperitoneal injection of
vehicle (0.1 mol/l citrate buffer, pH 4.5) alone or STZ at a dosage of 65 mg/kg
body wt dissolved in 0.1 mol/l citrate buffer.
Experimental design/surgical procedure. MI was induced in the diabetic
animals 30 days after the induction of diabetes as previously described (21).
Age-matched nondiabetic animals were used as comparable controls. The rats
were randomized into six groups: 1) control (nondiabetic) sham (CS), 2)
diabetic sham (DS), 3) control (nondiabetic) MI (CMI)  Ad.LacZ (CLZMI), 4)
CMI  (Ad.VEGFAd.Ang1) (CVAMI), 5) diabetic MI (DMI)  Ad.LacZ
(DLZMI), and 6) DMI  (Ad.VEGFAd.Ang1) (DVAMI). Ad.VEGF and
Ad.Ang1 were generous gifts from Dr. C. Li, East Tennessee State University
(18). Dr. Li’s groups veriﬁed the transfection efﬁciency of these adenoviral
vectors in vitro. Moreover, the authors demonstrated the synergistic effect of
coadministration of VEGF and Ang-1 in the ischemic rat myocardium (18).
Therefore, in our current investigation, the adenoviral dosage was used based
on Zhou et al.’s observations (18).
Immediately after MI, adenoviral vectors encoding for VEGF (Ad.VEGF,
6  10
7 pfu) and Ang-1 (Ad.Ang1, 1.5  10
5 pfu) were intramyocardially
administered in combination (in 100 l of PBS, using a 30-gauge needle) at
four sites at the border zone of the ischemic area in the CVAMI and DVAMI
groups. Adeno-LacZ (Ad.LacZ,6 10
7 pfu) was used as the control adenoviral
vector in the CLZMI and DLZMI groups, to nullify any possible effects exerted
by the vector itself.
For detailed descriptions of the materials and methods, please refer to the
supplementary material available in the online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-0336/DC1.
Statistical analysis. All data were analyzed by statistical software GraphPad
Prism PC software (San Diego, CA) Version 5.0. Statistical analysis was
performed using one-way ANOVA. Post hoc comparisons between the groups
were performed by Newman-Keuls multiple comparison test. Results are
presented as mean  SEM with P  0.05 used to indicate statistical
signiﬁcance.
RESULTS
The explanation of the result demonstrating the efﬁcacy of
intramyocardial gene delivery (Fig. 1A) has been included
in the supplementary material in the online appendix.
Immunohistochemical analysis of VEGF and Ang-1.
There was a decrease in the expression of VEGF and Ang-1
in the DS compared with CS (Fig. 1B and C). The MI
induced by left anterior descending artery (LAD) occlu-
sion seemed to trigger the expression of VEGF and Ang-1
in the nondiabetic control (CLZMI) animals to which
Ad.LacZ was administered. However, this infarction-trig-
gered expression of the angiogenic growth factors seemed
to be impaired in the diabetic animals (DLZMI, Fig. 1B
and C). The coadministration of Ad.VEGF and Ad.Ang1
in the nondiabetic (CVAMI) group markedly induced
expression of both growth factors. Similarly, the expres-
sion of VEGF and Ang-1 was restored markedly upon
treatment in the diabetic (DVAMI) myocardium (Fig. 1B
and C).
Biological effects of coexpression of VEGF and Ang-1
in the diabetic ischemic myocardium
Myocardial ﬁbrosis (Masson trichrome staining).
To determine the effect of the combination gene therapy
on the extent of myocardial ﬁbrosis, Masson trichrome
staining was performed on parafﬁn-embedded heart tissue
sections 7 and 30 days after the surgical intervention. After
7 days of MI, there was signiﬁcant increase in myocardial
ﬁbrosis in the DLZMI (30.8  2.8%) compared with the
CLZMI (23.9  0.5%) group. Upon therapy, the nondiabetic
CVAMI (20.2  0.4%) group demonstrated reduced colla-
gen deposition and ﬁbrosis compared with the respective
Ad.LacZ-treated nondiabetic CLZMI (23.9  0.5%) group.
Similarly, the diabetic MI group (DVAMI, 20.1  0.7%) that
received the therapy demonstrated signiﬁcantly reduced
myocardial collagen deposition and ﬁbrosis compared
with the respective Ad.LacZ-treated diabetic MI group
(DLZMI, 30.8  2.8%) (Fig. 2A). Figure 2A shows heart
tissue sections of the diabetic MI animals (DVAMI) that
received the therapy with less ﬁbrosis compared with the
Ad.LacZ-treated diabetic MI group (DLZMI), which
showed increased ﬁbrosis and ventricular dilatation. CS
and DS (Fig. 2A and B) represent the nondiabetic and
diabetic sham-operated groups with no signiﬁcant ﬁbrosis,
respectively. We observed a similar trend after 30 days of
intramyocardial gene therapy (Fig. 2B). The diabetic MI
group (DVAMI, 16.5  1.9%) that received the therapy
showed reduced myocardial collagen ﬁbrosis compared
with the respective Ad.LacZ-treated diabetic MI group
(DLZMI, 20.1  1.1%). Evidently there was a less promi-
nent scar extension in the treated diabetic rats (DVAMI)
compared with the Ad.LacZ-treated (DLZMI) animals (Fig.
2B).
Capillary density and arteriolar density. To under-
stand whether the reduction in ﬁbrosis was paralleled by
neoangiogenesis, we performed immunohistochemical
analysis for CD31 (endothelial cell marker) after 7 days of
the therapy, allowing the estimation of the density of
CD31-positive vessels (capillary density in counts/mm
2)
(Fig. 3A and B). There was a signiﬁcant decrease in the
capillary density in the DS-operated (2,706  122) and
Ad.LacZ-treated diabetic MI (DLZMI, 1,769  12) groups
compared with the CS-operated (3,619  214) and
Ad.LacZ-treated nondiabetic MI (CLZMI, 2,308  130)
groups, respectively. In the present study, we observed an
increase in the myocardial capillary vessel density in the
diabetic MI animals (DVAMI, 2,206  159) that received
the adenoviral vectors encoding VEGF and Ang-1 in
combination compared with the Ad.LacZ-treated dia-
betic MI (DLZMI, 1,769  12) animals. Similar results
were observed in the nondiabetic MI (CVAMI) group
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the Ad.LacZ-treated nondiabetic MI (CLZMI, 2,308 
130) group.
To analyze the angiogenic response to the therapy, the
arteriolar density (in counts/mm
2) was measured by im-
munostaining the heart tissue sections (Fig. 3C and D)
after 7 days of gene therapy for -smooth muscle actin.
There was a decrease in the arteriolar density in the
DS-operated (15.8  1.8) and Ad.LacZ-treated diabetic MI
(DLZMI, 16.3  2.9) groups compared with the CS-oper-
ated (28.3  1.3) and Ad.LacZ-treated nondiabetic MI
(CLZMI, 29.2  5.5) groups, respectively. In the present
study, we observed a signiﬁcant increase in the number of
arterioles (arteriolar density) in the diabetic MI (DVAMI)
animals that received the therapy (31.3  0.9) compared
with the Ad.LacZ-treated diabetic MI (DLZMI, 16.3  2.9)
group. Similar results were observed in the nondiabetic MI
(CVAMI) group that received the therapy (50.2  3.9)
compared with the Ad.LacZ-treated nondiabetic MI
(CLZMI, 29.2  5.5) group.
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FIG. 1. A: Representative micrographs showing the in vivo transfection efﬁciency of Ad.LacZ in the nondiabetic sham-operated groups.
Robust infection of the myocardium as assessed by -galactosidase staining in the viable cardiac muscle surrounding the sites of gene
transfer can be seen in the Ad.LacZ-transfected myocardium. B: Expression of VEGF as assessed by immunohistochemical staining. C:
Expression of Ang-1 as assessed by immunohistochemical staining. The decrease in the expression of VEGF and Ang-1 is evident in the
diabetic DS and DLZMI groups compared with the respective nondiabetic CS and CLZMI groups. Increase in the expression of VEGF and
Ang-1 can be seen in the groups that received the combination gene therapy (CVAMI and DVAMI) compared with their respective (CLZMI
and DLZMI) Ad.LacZ-treated groups. () represents representative micrographs showing the sections in which primary antibody was not
added to verify the speciﬁcity of the staining protocol. CS, nondiabetic control sham; DS, diabetic sham; CLZMI, nondiabetic control animals
that received Ad.LacZ injections; DLZMI, diabetic animals that received Ad.LacZ injections; CVAMI, nondiabetic control animals that
received combination gene therapy; and DVAMI, diabetic animals that received combination gene therapy. (A high-quality color digital
representation of this ﬁgure is available in the online issue.)
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tive effect of VEGF–Ang-1 therapy in the diabetic
ischemic myocardium
Effect of gene therapy on the expression of VEGF
and Flk-1. We observed a signiﬁcant reduction in the
expression of VEGF (1.75-fold) and Flk-1 (7.1-fold) 4 days
after the surgical procedure in the DS-operated animals
compared with the CS-operated animals (Fig. 4A and B).
Similarly, there was a signiﬁcant reduction in the expres-
sion of VEGF (2.5-fold) and Flk-1 (2.5-fold) in the DLZMI
group compared with the CLZMI group (Fig. 4C and D).
However, there was a signiﬁcant increase (1.6-fold) in
VEGF expression in the nondiabetic Ad.LacZ-treated MI
(CLZMI) group compared with the CS-operated animals.
This MI-induced increase in the expression of VEGF was
compromised in the diabetic MI (DLZMI) group that was
treated with Ad.LacZ. Upon treatment with a combination
of adenoviral vectors encoding VEGF and Ang-1 in the
nondiabetic MI (CVAMI) animals, we documented a signif-
icant increase in the levels of VEGF (1.3-fold) and Flk-1
(2.1-fold) 4 days after the gene transfer compared with the
Ad.LacZ-treated nondiabetic MI (CLZMI) group (Fig. 4C
and D). Similarly, we observed a signiﬁcant increase in the
expression of VEGF (1.9-fold) and Flk-1 (5.3-fold) in the
diabetic animals that received the therapy (DVAMI), 4
days after the combination gene transfer compared with
the Ad.LacZ-treated diabetic MI (DLZMI) group (Fig. 4C
and D).
Effect of gene therapy on the expression of Ang-1 and
Tie-2. In the present study, we observed a signiﬁcant
reduction in the expression of Ang-1 (2.2-fold) and Tie-2
(3.1-fold) 4 days after the surgical procedure, in the
DS-operated animals compared with CS-operated animals
(Fig. 4A and B). Upon treatment with a combination of
adenoviral vectors encoding VEGF and Ang-1 in the non-
diabetic MI (CVAMI) animals, we documented an increase
in the levels of Ang-1 (1.3-fold) and Tie-2 (1.3-fold) 4 days
after the gene transfer compared with the Ad.LacZ-treated
nondiabetic MI (CLZMI) group (Fig. 4C and D). Similarly,
we observed a signiﬁcant increase in the expression of
Ang-1 (4.0-fold) and Tie-2 (2.1-fold) in the diabetic animals
that received the therapy (DVAMI), 4 days after the
treatment, compared with the Ad.LacZ-treated diabetic MI
(DLZMI) group (Fig. 4C and D).
Effect of gene therapy on the expression of survivin.
There was a marked decrease in the expression of anti-
apoptotic protein survivin in the DS-treated (2.0-fold) and
diabetic Ad.LacZ-treated (DLZMI, 2.3-fold) MI groups
compared with the CS-operated and Ad.LacZ-treated non-
diabetic MI (CLZMI) groups, respectively (Fig. 4A and B).
We observed a signiﬁcant increase in the expression of
survivin in the nondiabetic animals that received the
therapy (CVAMI, 3.7-fold) 4 days after the treatment
compared with the Ad.LacZ-treated nondiabetic MI
(CLZMI) group (Fig. 4C and D). Similarly, we observed a
signiﬁcant increase in the expression of survivin in the
diabetic animals that received the therapy (DVAMI, 7.2-
fold) 4 days after the treatment compared with the
Ad.LacZ-treated diabetic MI (DLZMI) group (Fig. 4C and D).
Effect of gene therapy on the phosphorylation of
MK2. There was a marked decrease in the phosphoryla-
tion of mitogen-activated protein kinase–activated protein
kinase-2 (MK2, at Threonine 334) in the DS-treated (1.7-
fold) and diabetic Ad.LacZ-treated (DLZMI, 3.8-fold) MI
groups compared with the CS-operated and Ad.LacZ-
treated nondiabetic MI (CLZMI) groups, respectively, 2
days after the surgical procedure (Fig. 5A–D). We ob-
served a signiﬁcant increase in the phosphorylation of
MK2, 2 days after the treatment in the nondiabetic animals
that received the therapy (CVAMI, 1.3-fold), compared
with the Ad.LacZ-treated nondiabetic MI (CLZMI) group
(Fig. 5C and D). Similarly, we observed a signiﬁcant
increase in the phosphorylation of MK2, 2 days after the
treatment in the diabetic animals that received the therapy
(DVAMI, 3.9-fold), compared with the Ad.LacZ-treated
diabetic MI (DLZMI) group (Fig. 5C and D).
Similarly, the therapy signiﬁcantly increased the levels
of phosphorylated MK2 (p-MK2) 4 days after intervention
in both the DVAMI and CVAMI groups compared with the
DLZMI and CLZMI groups, respectively. However, there
was an evident decrease in the levels of p-MK2 in all the
FIG. 2. Effect of combination gene therapy on myocardial ﬁbrosis 7 and 30 days after gene therapy. A: Representative images show myocardial
infarct and ﬁbrosis after 7 days of MI and combination gene therapy. B: Representative images show myocardial infarct and ﬁbrosis after 30 days
of MI and combination gene therapy. There is no evident ﬁbrosis in the CS and DS groups. A thinner infarct and signiﬁcant ﬁbrosis is evident in
the CLZMI and DLZMI groups. Combination gene therapy in the CVAMI and DVAMI groups resulted in a thicker infarct containing islands of
viable cardiac tissue. CS, nondiabetic control sham; DS, diabetic sham; CLZMI, nondiabetic control animals that received Ad.LacZ injections;
DLZMI, diabetic animals that received Ad.LacZ injections; CVAMI, nondiabetic control animals that received combination gene therapy; and
DVAMI, diabetic animals that received combination gene therapy. (A high-quality color digital representation of this ﬁgure is available in the
online issue.)
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after the intervention.
Effect of gene therapy on the DNA binding activity of
NFB. Gel shift analysis 2 days after the surgical proce-
dure revealed signiﬁcant decrease in the DNA binding
activity of NFB in the DS animals compared with the
nondiabetic CS animals (Fig. 5E). NFB DNA binding
activity was signiﬁcantly elevated in the nondiabetic con-
trol animals that received the therapy (CVAMI) compared
with the Ad.LacZ-treated nondiabetic MI (CLZMI) group
(Fig. 5E). Similarly, the DNA binding activity of NFB was
signiﬁcantly restored upon coadministration of adenoviral
VEGF and Ang-1 in the diabetic animals (DVAMI) com-
pared with their respective Ad.LacZ-treated diabetic con-
trols (DLZMI) (Fig. 5E).
Preservation of myocardial functions after MI in the
diabetic myocardium through VEGF/Ang-1 combina-
tion gene therapy. To evaluate the in vivo functional
consequences of intramyocardial combination gene ther-
apy, we performed echocardiographic analysis on the
experimental animals in the different groups 30 days after
the gene transfer. Anterior wall thickness showed a de-
crease in all the groups subjected to MI compared with the
sham group, and the thinning of the anterior wall is greater
in the DLZMI group compared with the diabetic group
treated with VEGF and Ang-1 combination gene therapy
(data not shown). Larger left ventricular (LV) dimensions
at systole were also detected in diabetic sham (5.8  0.1)
compared with nondiabetic sham (4.5  0.1) groups. Four
weeks after LAD ligation, the left ventricular inner diam-
eters (LVIDs; mm) were signiﬁcantly larger in DLZMI rats
(7.4  0.3) compared with nondiabetic CLZMI (6.5  0.2)
rats (Fig. 6A and B). However, this increase in LV dimen-
sions was found to be prevented in the DVAMI (6.5  0.3)
groups compared with DLZMI (7.4  0.3) groups. Also,
nondiabetic CVAMI (5.9  0.1) groups showed better
improvement compared with nondiabetic CLZMI (6.5 
0.3) groups (Fig. 6A and B). Along with the LV dimensions,
we also noticed better systolic functions measured by
ejection fraction (in %) and fractional shortening (in %) in
all the control groups compared with their respective
diabetic groups. We observed a signiﬁcant increase in the
ejection fraction (%) in the combination gene therapy–
treated nondiabetic MI (CVAMI) group (57.3  0.8 vs.
50.1  2) and diabetic MI (DVAMI) group (53.9  2.2 vs.
43.8  2) compared with their respective Ad.LacZ-treated
nondiabetic (CLZMI) and diabetic (DLZMI) groups (Fig.
6C). Similarly, there was a signiﬁcant increase in fractional
shortening (%) in the combination gene therapy–treated
nondiabetic MI (CVAMI) group (31.2  0.5 vs. 26.6  1.2)
and diabetic MI (DVAMI) group (29.3  1.5 vs. 21.6  1.1)
compared with their respective Ad.LacZ-treated nondia-
betic (CLZMI) and diabetic (DLZMI) groups (Fig. 6D).
There were evident signs of bradycardia in all the diabetic
groups compared with their respective control groups. In
the present study, we observed improvement in the heart
rate (in beats/min) in the combination gene therapy–
treated diabetic MI (DVAMI) group (239.2  8.5) com-
pared with the Ad.LacZ-treated diabetic (DLZMI) group
(201.8  5.4) (Fig. 6E).
DISCUSSION
The angiogenic growth factors are downregulated in the
diabetic myocardium, in turn hampering myocardial col-
lateral vessel formation as an adaptation to ischemia (2).
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FIG. 3. Effect of combination gene therapy on capillary and arteriolar
density 7 days after the intervention. Representative images (A) and
graphical representation (B) of capillary density analysis among the
different groups (counts/mm
2). Representative images (C) and
graphical representation (D) of arteriolar density analysis among
the different groups (counts/mm
2). There was a signiﬁcant increase
in the capillary and arteriolar density in the CVAMI and DVAMI
groups compared with the CLZMI and DLZMI groups, respectively.
CS (black solid bar), nondiabetic control sham; DS (gray solid bar),
diabetic sham; CLZMI (white bar), nondiabetic control animals that
received Ad.LacZ injections; DLZMI (diagonal brick bar), diabetic
animals that received Ad.LacZ injections; CVAMI (wave bar), non-
diabetic control animals that received combination gene therapy;
and DVAMI (wide upward diagonal bar), diabetic animals that
received combination gene therapy. Values are presented as mean 
SEM. *P < 0.05 when DS is compared with CS, #P < 0.05 compared
with CLZMI, †P < 0.05 when DVAMI is compared with DLZMI. (A
high-quality color digital representation of this ﬁgure is available in
the online issue.)
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by means of gene therapy might aid in repairing the
process of impaired angiogenesis in the diabetic ischemic
myocardium. However, therapy using vectors encoding a
single angiogenic factor has shown less signiﬁcant im-
provement than what was expected, mainly because the
biological system requires a cascade of growth factors and
responsive intracellular signaling mechanisms for the de-
velopment of a fully functional vascular system (22–24).
Therefore, therapeutic angiogenesis is currently targeting
combinations of angiogenic molecules as a therapeutic
measure to induce myocardial angiogenesis (22). Ang-1 is
known to modify VEGF responses to neovascularization
by positively affecting vessel maturation and stability (25).
A strategy to locally overexpress VEGF and Ang-1 in
combination would prove beneﬁcial because, although
VEGF can take the lead in the process of neovasculariza-
tion, Ang-1 would be expected to support the maturation
of the newly formed vessels.
We observed signiﬁcant reduction in the expression of
VEGF and Ang-1 in the diabetic myocardium. However, MI
induced the expression of VEGF in the Ad.LacZ-treated
nondiabetic MI group. This increase in VEGF in the
nondiabetic MI group can be explained as an early adap-
tive response to the myocardial ischemia caused by LAD
ligation (26,27). This response was not seen in the diabetic
MI animals, conﬁrming the impairment of the angiogenic
machinery in the diabetic myocardium (28). In our present
study, the strategy of combination gene therapy markedly
increased the expression of VEGF and Ang-1 in the dia-
betic ischemic heart compared with the Ad.LacZ-treated
diabetic MI group.
The impairment of myocardial angiogenesis in a diabetic
condition has also been associated with compromised
signaling mechanisms through the receptors, Flk-1 for
VEGF and Tie-2 for Ang-1 (6,28,29). It is also known that
expression of these receptors is regulated by a positive-
feedback signaling mechanism where the ligand itself
controls the levels of expression of its own receptors
(6,30). The downregulation in the expression of the recep-
tors that we observed in the diabetic myocardium corre-
sponds to the impaired angiogenic signaling mechanisms
associated with a diabetic milieu. The increase in the
expression of the receptors Flk-1 and Tie-2 that we ob-
served upon gene therapy can be correlated to the in-
creased expression of their ligands: VEGF and Ang-1,
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fective in correcting the angiogenic machinery directly
associated with VEGF and Ang-1 that is impaired in the
diabetic myocardium.
The VEGF/Flk-1–induced effects on endothelial cell mi-
gration through p38 mitogen-activated protein kinase
(MAPK) activation are mediated primarily by phosphory-
lation and activation of the p38MAPK substrate MK2
(31,32). It was also reported that MK2 activation plays an
essential role in VEGF-induced actin reorganization, mi-
gration, and tubule formation in endothelial cells (33).
Recently, we have shown that ischemic preconditioning
induces VEGF expression followed by Flk-1 activation,
thereby activating an angiogenic signaling cascade by the
activation of p38MAPK and MK2 leading to the activation
of NFB (34). To elucidate the mechanism, we used
heterozygous Flk-1
/ and homozygous MK2
/ knockout
mice. Ischemic preconditioning in the Flk-1
/ mice failed
to bring about signiﬁcant phosphorylation of MK2 and
increase DNA binding activity of NFB compared with the
wild-type mice myocardium subjected to ischemic precon-
ditioning. Similarly, when we studied the effects of isch-
emic preconditioning in MK2
/ knockout mice, we
observed that the ischemic preconditioning–mediated ac-
tivation of NFB and the effective angiogenic response
were signiﬁcantly impaired when MK2 was knocked down
(34). Thus, we were able to conﬁrm that downstream of
Flk-1, activation of MK2 plays a crucial role in NFB
activation and angiogenesis in the myocardium. Our treat-
ment strategy signiﬁcantly increased the phosphorylation
of MK2, which can be associated with the increase in the
expression of VEGF and its receptor Flk-1, thereby trig-
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ischemic myocardium.
We have previously documented the effect of hypoxic
preconditioning on NFB activation and the role of NFB
in myocardial angiogenesis (35,36). Both VEGF and Ang-1
have been shown to increase the DNA binding activity of
NFB, thereby modulating endothelial cell proliferation,
survival, and migration (31). NFB has been shown to
activate several prosurvival genes, cytokines, and inhibi-
tors of apoptosis necessary for endothelial cell survival
(37). It was recently shown that combined gene therapy
using VEGF165 and Ang-1 signiﬁcantly reduced myocardial
infarct size through the induction of NFB activation (18).
Our treatment strategy has signiﬁcantly improved the DNA
binding activity of NFB in the diabetic ischemic myocar-
dium, thereby conﬁrming improvement in the angiogenic
signaling mechanism associated with increase in the ex-
pression of VEGF and Ang-1 and phosphorylation of MK2.
Survivin (an inhibitor of apoptosis) is upregulated by
VEGF and Ang-1 in the endothelial cells, thereby decreas-
ing apoptosis (38–41). It has been reported that activation
of NFB signaling contributes to endothelial cell survival
and tubular morphogenesis by the transactivation and
upregulation of the prosurvival protein survivin (42). The
reduced expression of survivin in the diabetic myocardium
can be correlated to the increased myocardial ﬁbrosis as
evidenced by trichrome staining. Our treatment strategy
leading to the coexpression of VEGF and Ang-1 might have
led to the increased expression of survivin through the
activation of NFB signaling in the diabetic ischemic
myocardium in the present study.
The cooperative effect of VEGF and Ang-1 coexpression
and the increase in the expression of their respective
receptors due to the therapy in mediating neovasculariza-
tion were conﬁrmed by a marked increase in the capillary
density and arteriolar density in the DVAMI group com-
pared with the Ad.LacZ-treated diabetic MI group. This
increase in vascularization as a result of the therapy might
have led to the signiﬁcant reduction in the myocardial
ﬁbrosis and marked increase in the islands of viable
cardiac tissue in the infarct and peri-infarct regions of the
diabetic infarcted heart upon therapy. Although stabiliza-
tion of the VEGF-induced neovascularization by Ang-1 is the
most likely reason for the observed increase in capillary and
arteriolar density in the surviving myocardium immediately
adjacent to the infarct, the possibility of VEGF- and Aug-1–
induced cell survival, preservation of existing vessels, and a
resultant direct effect on myocardial repair cannot be ruled
out. Moreover, there is evidence that suggests that post-MI
vascular repair is not dependent solely on the activation and
participation of resident endothelial cells, but may also
reﬂect an increased bone marrow–derived endothelial pro-
genitor cell mobilization and homing, which are in turn
activated by overexpression of both VEGF and Ang-1 (43,44).
Therefore, there is a possibility that our combination gene
therapy might have induced endothelial progenitor cell hom-
ing to the diabetic infarcted myocardium aiding in the
reparative process.
A number of preclinical and clinical studies have shown
structural changes in parallel with the functional changes
combination gene therapy; and DVAMI (wide upward diagonal bar),
diabetic animals that received combination gene therapy. Values given
as mean  SEM. *P < 0.05 when DS is compared with CS, #P < 0.05
compared with CLZMI, †P < 0.05 when DVAMI is compared with
DLZMI.
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myocardium of nondiabetic subjects exhibits hyperkinesia
to compensate for the infarcted myocardium in an attempt
to maintain cardiac output. When it comes to a diabetic
subject, in addition to the already compromised cardiac
functions, after an MI, the myocardium is unable to
achieve this compensatory enhancement in function due
to signiﬁcant ventricular remodeling, myocardial ﬁbrosis,
and collagen deposition, which in turn further reduces
myocardial functional capability (45). In our current study,
the reduced ﬁbrosis and improved vascularization as a
result of the therapy might have caused the improvement
in the myocardial functions 30 days after MI in the diabetic
rats. The therapy resulted in preservation of myocardial
thickness and less prominent collagen deposition. Consis-
tent with other reports, though bradycardia was evident in
all the diabetic groups, the heart rate signiﬁcantly im-
proved upon treatment (46). The treatment resulted in
better contractile function and suppression of the progres-
sive cardiac failure that is associated with ventricular
remodeling in a diabetic infarcted heart.
To the best of our knowledge our results have docu-
mented for the ﬁrst time that intramyocardial coadminis-
tration of adenoviral vectors encoding VEGF and Ang-1
induces angiogenesis and vessel maturation, thereby ren-
dering cardioprotection against the ischemic stress in-
duced by MI in STZ-induced type 1 diabetic rats. The
therapy signiﬁcantly reduced the ventricular remodeling
as evidenced by the signiﬁcant reduction in the collage-
nous ﬁbrotic tissue and improvement in the myocardial
functions in conjunction with signiﬁcant increase in the
levels of VEGF and its receptor Flk-1, Ang-1 and its
receptor Tie-2, p-MK2, and antiapoptotic survivin. Our
unique and promising preclinical ﬁndings therefore sup-
port the development of a combination gene therapy for
therapeutic myocardial angiogenesis and call for the initi-
ation of a clinical trial to assess the efﬁcacy of this unique
therapeutic strategy in the treatment of diabetes-related
human heart failure.
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